
Opinion|Videos|December 3, 2024
The Impact of Biomarkers and Modern Disease-Modifying Therapies in MS
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Panelists discuss how modern multiple sclerosis (MS) management has evolved from symptomatic treatment to a proactive, personalized approach leveraging advanced biomarkers and sophisticated disease-modifying therapies. The focus has shifted toward early intervention, precise monitoring, and comprehensive disease control, significantly improving patient outcomes and quality of life.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please share how your management of MS has changed in recent years with the availability of biomarkers and highly efficacious disease-modifying therapies.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tau PET Tracer MK-6240 for Alzheimer Diagnostic Workup
2
FDA Clears Phase 2 Trial for Demyelinating Agent Lucid-MS in Progressive Multiple Sclerosis
3
Zoster Vaccine Shows Strong Effectiveness in Patients With Multiple Sclerosis
4
Voyager to Advance 2 Tau-Targeted Alzheimer Therapies Toward Key Clinical Milestones
5


















